OMRF researchers have identified a compound that has been successfully shown to decrease both tumor size and tumor vasculature in animal models of Glioblastoma Multiforme (GBM), an aggressive type of malignant brain tumor.
Year Founded: 2012
Year Partnered: 2012
Category: Biotech/Pharma
Fund: Oklahoma Seed Capital Fund
Acquired in 2016 by Oblato, Inc.
